Glutathione peroxidases as oncotargets
Metrics: PDF 1050 views | HTML 2377 views | ?
Yang Jiao1,*, Yirong Wang2,*, Shanchun Guo3 and Guangdi Wang3
1 Department of Stomatology, PLA Army General Hospital, Beijing, P.R. China
2 State Key Laboratory of Military Stomatology & National Clinical Research Center for Oral Diseases & Shaanxi Key Laboratory of Oral Diseases, Department of Operative Dentistry and Endodontics, School of Stomatology, The Fourth Military Medical University, Xi’an, P.R. China
3 RCMI Cancer Research Center and Department of Chemistry, Xavier University of Louisiana, New Orleans, LA, USA
* These authors have contributed equally to this work
Shanchun Guo, email:
Guangdi Wang, email:
Keywords: glutathione peroxidases, oxidative stress, reactive oxygen species, carcinogenesis, drug target
Received: November 04, 2016 Accepted: June 20, 2017 Published: August 16, 2017
Oxidative stress is a disturbance in the equilibrium among free radicals, reactive oxygen species, and endogenous antioxidant defense mechanisms. Oxidative stress is a result of imbalance between the production of reactive oxygen and the biological system’s ability to detoxify the reactive intermediates or to repair the resulting damage. Mounting evidence has implicated oxidative stress in various physiological and pathological processes, including DNA damage, proliferation, cell adhesion, and survival of cancer cells. Glutathione peroxidases (GPxs) ( ) are an enzyme family with activity whose main biological roles are to protect organisms from oxidative damage by reducing as well as free hydrogen peroxide. Currently, 8 sub-members of GPxs have been identified in humans, all capable of reducing H2O2 and soluble fatty acid hydroperoxides. A large number of publications has demonstrated that GPxs have significant roles in different stages of carcinogenesis. In this review, we will update recent progress in the study of the roles of GPxs in cancer. Better mechanistic understanding of GPxs will potentially contribute to the development and advancement of improved cancer treatment models.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.